Cargando…
Systemic vasculitis associated with vemurafenib treatment: Case report and literature review
RATIONALE: Vemurafenib, an inhibitor of mutated B-rapidly accelerated fibrosarcoma, is frequently used in the treatment of melanoma and Erdheim–Chester disease (ECD) patients. Inflammatory adverse effects have been increasingly reported after vemurafenib treatment. PATIENT CONCERNS AND DIAGNOSE: We...
Autores principales: | Mirouse, Adrien, Savey, Léa, Domont, Fanny, Comarmond, Cloé, Barete, Stéphane, Plaisier, Emmanuelle, Rouvier, Philippe, Cacoub, Patrice, Saadoun, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120889/ https://www.ncbi.nlm.nih.gov/pubmed/27861332 http://dx.doi.org/10.1097/MD.0000000000004988 |
Ejemplares similares
-
Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals
por: Comarmond, Cloé, et al.
Publicado: (2020) -
Ethnicity and association with disease manifestations and mortality in Behçet’s disease
por: Savey, Lea, et al.
Publicado: (2014) -
Efficacy of Anti-TNFα in Severe and Refractory Neuro-Behcet Disease: An Observational Study
por: Desbois, Anne Claire, et al.
Publicado: (2016) -
Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis
por: Jarrot, Pierre-Andre, et al.
Publicado: (2016) -
COVID-19 outcomes in giant cell arteritis and polymyalgia rheumatica versus rheumatoid arthritis: A national, multicenter, cohort study
por: Vieira, Matheus, et al.
Publicado: (2022)